Featured
-
-
Article
| Open Access
Systematic review and meta-analysis for a Global Patient co-Owned Cloud (GPOC)
Use of cloud-based personal health records are increasing globally. Here, authors introduce the Global Patient co-Owned Cloud (GPOC) concept. The systematic review and meta-analysis examine factors like data security, efficiency, privacy, and cost. It aims to establish a scientific basis for a GPOC, which may disseminate global artificial intelligence for healthcare.
- Niklas Lidströmer
- , Joe Davids
- & Eric Herlenius
-
Article
| Open Access
Cost-effectiveness requirements for implementing artificial intelligence technology in the Women’s UK Breast Cancer Screening service
AI technology has the potential to substitute a human reader to aid services struggling to recruit staff or meet patient demand. Here, the authors show that the technology is a viable and potentially cost-effective strategy for use in the NHS.
- Armando Vargas-Palacios
- , Nisha Sharma
- & Gurdeep S. Sagoo
-
Article
| Open Access
Benefit-cost analysis of coordinated strategies for control of rabies in Africa
Control of rabies in Africa through mass vaccination of dogs may be compromised by cross-border transmission. Here, the authors use mathematical modelling and a benefit-cost analysis to demonstrate that coordinating rabies control measures across borders could lead to the elimination of dog rabies in Africa.
- A. Bucher
- , A. Dimov
- & J. Zinsstag
-
Article
| Open Access
Modelling the economic burden of SARS-CoV-2 infection in health care workers in four countries
Health care workers were at high risk of SARS-CoV-2 infection in the early stage of the pandemic, and this had knock-on effects including secondary infections and disruptions in health service delivery. Here, the authors estimate the economic impacts of SARS-CoV-2 infections in health care workers at the society level in five low- and middle-income country settings.
- Huihui Wang
- , Wu Zeng
- & Mickey Chopra
-
Comment
| Open AccessA broader perspective on the economics of malaria prevention and the potential impact of SARS-CoV-2
Economic evaluations of public health interventions to prevent malaria should consider the adoption of wider perspectives and the inclusion of non-health impacts, particularly economic development outcomes, such as education. This is especially relevant in malaria elimination settings and in the context of the current SARS-CoV-2 pandemic.
- Elisa Sicuri
- , Francesco Ramponi
- & Francisco Saúte
-
Article
| Open Access
Clinical outcomes and cost-effectiveness of COVID-19 vaccination in South Africa
Cost, supply and logistics present challenges to COVID-19 vaccine rollout in low and middle income countries. Here, the authors model vaccination programmes in South Africa and demonstrate the importance of the pace of vaccine rollout, with even moderately efficacious vaccines likely to be cost-effective.
- Krishna P. Reddy
- , Kieran P. Fitzmaurice
- & Mark J. Siedner
-
Article
| Open Access
Potential health and economic impacts of dexamethasone treatment for patients with COVID-19
Dexamethasone has been shown to have survival benefits for critically ill patients hospitalised with COVID-19 in the UK. Here, the authors estimated the number of lives that could be saved through a UK and global roll out of the drug and demonstrate that it is a cost-effective option.
- Ricardo Águas
- , Adam Mahdi
- & Mesulame Namedre
-
Article
| Open Access
Open data on industry payments to healthcare providers reveal potential hidden costs to the public
Industry payments to healthcare providers for non-research costs are common in the US. Linking Medicare and Open Payments data, the authors find that providers receiving more industry payments tend to bill higher drug and medical costs, and this association is stronger in more conservative states.
- Jorge Mejia
- , Amanda Mejia
- & Franco Pestilli
-
Article
| Open Access
The economics of malaria control in an age of declining aid
Foreign aid is necessary to control tropical diseases in endemic countries. Here the authors outline the steps taken to control malaria in Africa since 2000 and present an economic model to propose that US$25−30 per capita will be needed to avoid a disease trap.
- Eric Maskin
- , Célestin Monga
- & Jean-Claude Berthélemy
-
Article
| Open Access
Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis
Several drug combinations with different properties are used for malaria treatment. Here, Okell et al. use a mathematical model to simulate malaria transmission and treatment with two drug combinations in Africa, and find that locally optimized policies can be highly cost effective for reducing malaria burden.
- Lucy C. Okell
- , Matthew Cairns
- & Azra C. Ghani
Cost-effectiveness and cost-utility of a digital technology-driven hierarchical healthcare screening pattern in China